{"docstore/metadata": {"7d512a61-de38-447a-a6c1-9f55ead26529": {"doc_hash": "7fa117cfbe9e80706507766cb7c244119a7fca45f272cefa968934ddf1ed005f"}, "f2c389ef-7ac9-4889-a00e-e9422247cf43": {"doc_hash": "e540ec186d0a86923cc049e8098f58b143d751207978798f25e29b7e6b311980"}, "9b36fe5b-efea-4cca-bf56-3159d8a45485": {"doc_hash": "115aacedd26f7f43ea202ade894a7b5d38090d3f3513a482642a8597bca168a3"}, "7adff462-401d-4722-a64b-c281aac4c2c1": {"doc_hash": "d09852c76069dec0f97a78113fd60dbf4d18b3148f41f3a42ab24577883455d0"}, "c7e54831-4721-4b3b-becb-0995300c1e35": {"doc_hash": "9d4ada45e1b1635a4e5490620f40b0af2dc5a3aa595836f7d2b68c9d3c784b08"}, "bce6c492-eab6-4fe5-a7c0-263a4c76df20": {"doc_hash": "b78c6a534b00989d2fd27e5ef84acc89c314a6d290d441ec3f2294b607d53715"}, "63c99209-dd7d-4863-bfb9-d159fbe4da6c": {"doc_hash": "2ca8be1964fa9fbbe4e3e76c2a6fb9775ff21560a10ac3fa1ca36dc7c5f194a9"}, "d53c4a56-25ca-4765-8555-2c6e73f1be68": {"doc_hash": "4ef50474bd23b0b178aac96130ca8701fc6a74349ab34ed8244d8851b534b51e"}, "cc99e29d-03d8-4cdf-9d55-2978558f6e74": {"doc_hash": "cfe853adc41ec0ec99921fc8dfbe856534c386cccf398c7bdfce8dcaf992a124"}, "c75c254d-cbe8-4556-9976-a83caa83d43f": {"doc_hash": "ab6ba3861358547bb4aee73172a98568aa519cd3b43554594d526b846925eb5d"}, "043f045f-3980-45ea-b870-2b2b83c018f4": {"doc_hash": "ff0c50bdd03af133ecbecf5713d06f7bab771040447e7e77283607cefb1c0dbe"}, "7c90146e-501d-474d-9c7f-ab57b5351320": {"doc_hash": "bd284664c3876a5fbdce61884832e83878ec2effaa04213d6b6557f98792cc99"}, "34644c3f-64c6-4384-9204-059621682d40": {"doc_hash": "3073f938fe5a37ad96cabf2e2e0e1505f387dd2865c3d879b45132bdd4d93ef5"}, "f4bd806b-ad5e-4419-adc6-54afc3be9944": {"doc_hash": "38a6018dedf1d4a78c3772406f0937ff38f171b43eb215ca46aaa6e7a345c32d"}, "42955d0f-bba4-4584-a384-663bd0842e1c": {"doc_hash": "3caed54db1dd2da1f1a5fb0b0cb6b5a1b297b3e51851e0494f66f0ac19b688d4"}, "3a90324c-72d1-4b69-94a0-80ddaf24396c": {"doc_hash": "a5079af7565c72d83fbf87c661f1b73bf6d014988ea766f12ebc34a1ed867086"}, "4883ada8-3e80-4878-960d-f711f276cea5": {"doc_hash": "1ea26f987c168c3db7bfd1d1da7cbf138b4047d74eca53a8a90867291b8fe3c8"}, "1768b669-12b2-4cd6-b9d2-6ae05824fafe": {"doc_hash": "c6ec30097c47cf11288ac255381341a26bfbdceaf175c5654f085db8a4a923e9"}, "fd273028-a761-479a-955b-db9a96ef0aed": {"doc_hash": "7fa117cfbe9e80706507766cb7c244119a7fca45f272cefa968934ddf1ed005f", "ref_doc_id": "7d512a61-de38-447a-a6c1-9f55ead26529"}, "66c3d439-7533-4971-9eaf-9ef123ea21fa": {"doc_hash": "77299140db02b349c5eb2f0eacd7d5acbe02a55fb2340b9de5b0822932ac9522", "ref_doc_id": "f2c389ef-7ac9-4889-a00e-e9422247cf43"}, "e440c936-8845-41ef-ae37-81ee5b5bfeda": {"doc_hash": "37f8c0b23ad49fc6f9986b9858cbcf7a4cce19324da655f4e57affdef0304935", "ref_doc_id": "f2c389ef-7ac9-4889-a00e-e9422247cf43"}, "5214b239-5dd4-4c82-81af-571cecb32e0d": {"doc_hash": "115aacedd26f7f43ea202ade894a7b5d38090d3f3513a482642a8597bca168a3", "ref_doc_id": "9b36fe5b-efea-4cca-bf56-3159d8a45485"}, "7d003f25-cc6b-4003-8a6c-48655b2ab041": {"doc_hash": "d09852c76069dec0f97a78113fd60dbf4d18b3148f41f3a42ab24577883455d0", "ref_doc_id": "7adff462-401d-4722-a64b-c281aac4c2c1"}, "a0ebe0e9-c3c1-4dd4-a36c-113c9f7532e0": {"doc_hash": "9d4ada45e1b1635a4e5490620f40b0af2dc5a3aa595836f7d2b68c9d3c784b08", "ref_doc_id": "c7e54831-4721-4b3b-becb-0995300c1e35"}, "478a69a4-5c64-496b-b17d-9640c16962a0": {"doc_hash": "b78c6a534b00989d2fd27e5ef84acc89c314a6d290d441ec3f2294b607d53715", "ref_doc_id": "bce6c492-eab6-4fe5-a7c0-263a4c76df20"}, "956284ef-c6f5-4bcf-846b-dda4cd866cb5": {"doc_hash": "2ca8be1964fa9fbbe4e3e76c2a6fb9775ff21560a10ac3fa1ca36dc7c5f194a9", "ref_doc_id": "63c99209-dd7d-4863-bfb9-d159fbe4da6c"}, "41336ba1-4aec-482d-899c-55fec953b60f": {"doc_hash": "6ef749fb012cca5cd1ca1db63b4a42e5090d55b91bb7f465cf590e9abbd261e4", "ref_doc_id": "d53c4a56-25ca-4765-8555-2c6e73f1be68"}, "d2fd057b-6c93-4bfc-ad5f-68e11eddeba5": {"doc_hash": "e0296851e89d30d7085d67910cc93d641f3d89a4485a0de27a6d29b30cb76542", "ref_doc_id": "d53c4a56-25ca-4765-8555-2c6e73f1be68"}, "39723756-c275-4326-b9ab-e6506069209e": {"doc_hash": "cfe853adc41ec0ec99921fc8dfbe856534c386cccf398c7bdfce8dcaf992a124", "ref_doc_id": "cc99e29d-03d8-4cdf-9d55-2978558f6e74"}, "9a2d691b-a8ae-4891-b3d7-f9b9b49ae8c9": {"doc_hash": "ab6ba3861358547bb4aee73172a98568aa519cd3b43554594d526b846925eb5d", "ref_doc_id": "c75c254d-cbe8-4556-9976-a83caa83d43f"}, "4cd0d83a-094b-4b50-92eb-580cd03b4585": {"doc_hash": "ff0c50bdd03af133ecbecf5713d06f7bab771040447e7e77283607cefb1c0dbe", "ref_doc_id": "043f045f-3980-45ea-b870-2b2b83c018f4"}, "b40e3edc-bf1f-4bcf-be52-7fa01a44a1aa": {"doc_hash": "bd284664c3876a5fbdce61884832e83878ec2effaa04213d6b6557f98792cc99", "ref_doc_id": "7c90146e-501d-474d-9c7f-ab57b5351320"}, "cd9e472e-6a71-49d4-a183-96702490dcb1": {"doc_hash": "e2c7f835ce4d64beb22a4f4b33cd1c75aa7a945859c5d56a8b7f7aba8d2519bc", "ref_doc_id": "34644c3f-64c6-4384-9204-059621682d40"}, "99b5201a-d4cf-4958-8043-462c16b34097": {"doc_hash": "33a989b6528fd38471b854ddab80a3d552750967fa7873ace96910485a7c984c", "ref_doc_id": "34644c3f-64c6-4384-9204-059621682d40"}, "887857b5-bae5-44a5-9087-6a2a6db068cb": {"doc_hash": "38a6018dedf1d4a78c3772406f0937ff38f171b43eb215ca46aaa6e7a345c32d", "ref_doc_id": "f4bd806b-ad5e-4419-adc6-54afc3be9944"}, "bae3a263-131c-4c30-a959-d2c6be021046": {"doc_hash": "3caed54db1dd2da1f1a5fb0b0cb6b5a1b297b3e51851e0494f66f0ac19b688d4", "ref_doc_id": "42955d0f-bba4-4584-a384-663bd0842e1c"}, "252914df-5a2c-47ad-9c29-ba7e7b11f2c7": {"doc_hash": "f3cc69bd964dc6750ab5b91663c1f4c40fad441354c20215a78d609fd7da7aa3", "ref_doc_id": "3a90324c-72d1-4b69-94a0-80ddaf24396c"}, "0a6a0552-3563-4734-923e-6f7e02e6b9cb": {"doc_hash": "8d1c73615230dfd4d4a779586e1b778f999e5400fc697c847cc5256571659abe", "ref_doc_id": "3a90324c-72d1-4b69-94a0-80ddaf24396c"}, "2398bac3-473e-4e4b-bbd8-9fc37c331e49": {"doc_hash": "6b0dde24d6ff645a1d7188af8a0b3ef051814abcdb49daa76c8295f1f60e8ef5", "ref_doc_id": "4883ada8-3e80-4878-960d-f711f276cea5"}, "4b011f2c-8d09-41fb-993e-f3f3c0d71e17": {"doc_hash": "51ce866325366e772483c1be946b93e213e53a54c00abb7cac5bf730aa215729", "ref_doc_id": "4883ada8-3e80-4878-960d-f711f276cea5"}, "005d32e3-5583-4585-86d2-7ca38a37a851": {"doc_hash": "c4c7f3bd0c841069fd4dcca42f6b157f6ae4b40dd6b9979938835275b0f67750", "ref_doc_id": "4883ada8-3e80-4878-960d-f711f276cea5"}, "0874d86f-4b03-4b83-ad4d-a0dbdb94acde": {"doc_hash": "c6ec30097c47cf11288ac255381341a26bfbdceaf175c5654f085db8a4a923e9", "ref_doc_id": "1768b669-12b2-4cd6-b9d2-6ae05824fafe"}}, "docstore/data": {"fd273028-a761-479a-955b-db9a96ef0aed": {"__data__": {"id_": "fd273028-a761-479a-955b-db9a96ef0aed", "embedding": null, "metadata": {"page_label": "1", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7d512a61-de38-447a-a6c1-9f55ead26529", "node_type": "4", "metadata": {"page_label": "1", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "7fa117cfbe9e80706507766cb7c244119a7fca45f272cefa968934ddf1ed005f", "class_name": "RelatedNodeInfo"}}, "text": "RESEARCH ARTICLE\nHealth Effects of Long-Term Rapamycin\nTreatment: The Impact on Mouse Health of\nEnteric Rapamycin Treatment from Four\nMonths of Age throughout Life\nKathleen E. Fischer1,2\u00a4a*, Jonathan A. L. Gelfond3, Vanessa Y. Soto1, Chul Han4,\nShinichi Someya4, Arlan Richardson1,5\u00a4b, Steven N. Austad1,5\u00a4a\n1 Barshop Institute for Longevity & Aging Studies, University of Texas Health Science Center San Antonio,\nSan Antonio, Texas, United States of America,2 Department of Physiology, University of Texas Health\nScience Center San Antonio, San Antonio, Texas, United States of America,3 Department of Epidemiology\n& Biostatistics, University of Texas Health Science Center San Antonio, San Antonio, Texas, United States of\nAmerica, 4 Departments of Aging and Geriatric Research, University of Florida, Gainesville, Florida, United\nStates of America,5 Department of Cellular & Structural Biology, University of Texas Health Science Center\nSan Antonio, San Antonio, Texas, United States of America\n\u00a4a Current address: Department of Biology, University of Alabama at Birmingham, Birmingham, Alabama,\nUnited States of America\n\u00a4b Current address: University of Oklahoma Health Science Center & Oklahoma City Veteran Administration\nMedical Center, Oklahoma City, Oklahoma, United States of America\n* fischerk@uab.edu\nAbstract\nRapamycin, an mTOR inhibitor, has been shown to extend lifespan in a range of model or-\nganisms. It has been reported to extend lifespan in multiple strains of mice, administered\nchronically or acutely early or late in life. The ability of rapamycin to extend health (health-\nspan) as opposed to life is less well documented. To assess the effects chronic rapamycin\ntreatment on healthspan, enteric rapamycin was given to male and female C57BL/6J mice\nstarting at 4 months of age and continued throughout life. Repeated, longitudinal assess-\nments of health in individual animals were made starting at 16 months of age (=12 months\nof treatment) until death. A number of health parameters were improved (female grip\nstrength, female body mass and reduced sleep fragmentation in both sexes), others\nshowed no significant difference, while at least one (male rotarod performance) was nega-\ntively affected. Rapamycin treatment affected many measures of health in a highly sex-spe-\ncific manner. While sex-specific phenotypic effects of rapamycin treatment have been\nwidely reported, in this study we document sex differences in thedirection of phenotypic\nchange. Rapamycin-fed males and females were both significantly different from controls;\nhowever the differences were in the opposite direction in measures of body mass, percent\nfat and resting metabolic rate, a pattern not previously reported.\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 1/1 8\nOPEN ACCESS\nCitation: Fischer KE, Gelfond JAL, Soto VY , Han C,\nSomeya S, Richardson A, et al. (2015) Health Effects\nof Long-Term Rapamycin Treatment: The Impact on\nMouse Health of Enteric Rapamycin Treatment from\nFour Months of Age throughout Life. PLoS ONE\n10(5): e0126644. doi:10.1371/journal.pone.0126644\nAcademic Editor:Christoph Englert, Leibniz Institute\nfor Age Research - Fritz Lipmann Institute (FLI),\nGERMANY\nReceived: November 3, 2014\nAccepted: April 4, 2015\nPublished: May 15, 2015\nCopyright: This is an open access article, free of all\ncopyright, and may be freely reproduced, distributed,\ntransmitted, modified, built upon, or otherwise used\nby anyone for any lawful purpose. The work is made\navailable under theCreative Commons CC0public\ndomain dedication.\nData Availability Statement:Data will be available\nfor download athttp://uab.edu/cas/biology/people/\nfaculty-directory/steven-n-austad/DataSets ; Data is\navailable athttp://dx.doi.org/10.6084/m9.figshare.\n1376133.\nFunding: Financial Support was provided by the San\nAntonio Nathan Shock Aging Center to AR (P30-\nAG13319) (http://www.nia.nih.gov/research/dab/\nnathan-shock-centers-excellence), National Institutes\nof Health RC2 Grand Opportunity grant to AR (AG\n036613) (http://grants.nih.gov/grants/guide/rfa-files/", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66c3d439-7533-4971-9eaf-9ef123ea21fa": {"__data__": {"id_": "66c3d439-7533-4971-9eaf-9ef123ea21fa", "embedding": null, "metadata": {"page_label": "2", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2c389ef-7ac9-4889-a00e-e9422247cf43", "node_type": "4", "metadata": {"page_label": "2", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "e540ec186d0a86923cc049e8098f58b143d751207978798f25e29b7e6b311980", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e440c936-8845-41ef-ae37-81ee5b5bfeda", "node_type": "1", "metadata": {}, "hash": "205611af8a762481961002203ceeddf2f591d2e656eb24bd8340d454d12278d5", "class_name": "RelatedNodeInfo"}}, "text": "Introduction\nRapamycin, a potent mTOR inhibitor, has been reported to extend lifespan in both vertebrate\nand invertebrate model organisms. In at least 7 previous studies mouse lifespan has been\nshown to be extended in both sexes, in heterogeneous and several inbred strains, with rapamy-\ncin administered in food (enteric rapamycin) or via injection, chronically or acutely, at a variety\nof ages [1\u201311]. However complete loss of mTOR signaling causes significant defects in growth\nand/or development in worms (C. elegans) and flies (D. melanogaster), and is embryonic lethal\nin mice [10]. The mTOR signaling network plays a pivotal role in promoting anabolic and in-\nhibiting catabolic processes. mTOR activation stimulates ribosome biogenesis, protein synthe-\nsis and the import of nutrients into cells [12]; conversely, reduction or inhibition of mTOR\nactivity decreases mRNA translation, increases autophagy, retards protein synthesis, slows cell\ngrowth and proliferation and enhances stress responsive transcription.\nBecause rapamycin treatment increases longevity across phylogenetically distant groups and\nis already FDA-approved for use in humans, it may represent a viable intervention to extend\nhuman life as well. Its effects on health have been less well documented. Recent evidence sug-\ngests that rapamycin may improve resistance to multiple, age-associated degenerative processes\nin mice. This offers the tantalizing possibility that rapamycin could extend the length ofhealthy\nhuman life. In mouse models rapamycin has been shown to delay the onset of Alzheimer\u2019s pa-\nthology [13, 14], reduce the incidence of some cancers [4, 15\u201317], inhibit the development of\natherosclerotic plaques [18], maintain cardiac function [1], enhance vaccine response in aged\nanimals [5], delay age-related cognitive decline [19\u201321], and maintain some aspects of activity,\nmotor function and behavior [1, 4, 11, 15, 16, 21\u201323]. On the other hand, rapamycin has been\nreported to have deleterious effects in mice, such as glucose intolerance and insulin resistance\n[24], testicular degeneration, increased cataract severity [15] and nephrotoxicity [21]. In some\ncases, results from different studies are inconsistent. For instance, some the beneficial effects on\nage-related changes found in one study (e.g. improved cardiac function with age [1] or in-\ncreased insulin sensitivity [25]) have not been found in others (e.g. cardiac function [21], insulin\nsensitivity [24]). The potential use of rapamycin to address age-related diseases is promising,\nbut the lack of consistent findings with respect to health in mice is reason for concern.\nThere are additional reasons for caution in considering rapamycin as a potential aging inter-\nvention. The use of rapamycin as part of immunosuppressive therapy after organ transplanta-\ntion may be a reason for concern given age-related decline in immune function [26, 27];\nhowever, recent research suggests that, in mice and primates, enterically delivered rapamycin\nmay enhance rather than suppress some aspects of immune response (e.g. [28, 29]). Secondly,\nbecause it inhibits protein synthesis, cellular processes requiringde novoprotein synthesis such\nas growth, tissue repair and regeneration may be compromised by chronic rapamycin adminis-\ntration. For example, some rodent studies have observed that mTOR inhibition retards recov-\nery from skeletal [30] or cardiac muscle injury [31]. Additionally, rapamycin has been reported\nto negatively affect neuronal long-term potentiation and memory consolidation [32, 33]. Both\nhuman and rodent studies have associated inhibition of mTOR with insulin resistance [34];\nhowever recent studies have suggested that these effects are transitory and diminish as duration\nof chronic treatment increases [1, 22].\nExtending lifespan without delaying or diminishing age-related morbidity is not a desirable\ngoal and rapamycin\u2019s effects on healthspan were anything but clear. We therefore initiated a lon-\ngitudinal study of rapamycin\u2019s impact on longevity and a range of health parameters by treating\nC57BL/6 mice of both sexes with enteric rapamycin started at two distinct ages, 19 months (=\nold-fed or OF mice) and 4 months (= young-fed or YF mice) and continuing treatment through-\nout life. OF results have been previously published [11].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e440c936-8845-41ef-ae37-81ee5b5bfeda": {"__data__": {"id_": "e440c936-8845-41ef-ae37-81ee5b5bfeda", "embedding": null, "metadata": {"page_label": "2", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2c389ef-7ac9-4889-a00e-e9422247cf43", "node_type": "4", "metadata": {"page_label": "2", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "e540ec186d0a86923cc049e8098f58b143d751207978798f25e29b7e6b311980", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66c3d439-7533-4971-9eaf-9ef123ea21fa", "node_type": "1", "metadata": {"page_label": "2", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "77299140db02b349c5eb2f0eacd7d5acbe02a55fb2340b9de5b0822932ac9522", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, rapamycin has been reported\nto negatively affect neuronal long-term potentiation and memory consolidation [32, 33]. Both\nhuman and rodent studies have associated inhibition of mTOR with insulin resistance [34];\nhowever recent studies have suggested that these effects are transitory and diminish as duration\nof chronic treatment increases [1, 22].\nExtending lifespan without delaying or diminishing age-related morbidity is not a desirable\ngoal and rapamycin\u2019s effects on healthspan were anything but clear. We therefore initiated a lon-\ngitudinal study of rapamycin\u2019s impact on longevity and a range of health parameters by treating\nC57BL/6 mice of both sexes with enteric rapamycin started at two distinct ages, 19 months (=\nold-fed or OF mice) and 4 months (= young-fed or YF mice) and continuing treatment through-\nout life. OF results have been previously published [11]. Consistent with our previous findings,\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 2/1 8\nRFA-OD-09-004.html), and NIH training grant (T32\nAG 021890) to SNA (http://www.nia.nih.gov/research/\ndea/institutional-training-grants).\nCompeting Interests:The authors have declared\nthat no competing interests exist.", "mimetype": "text/plain", "start_char_idx": 3428, "end_char_idx": 4686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5214b239-5dd4-4c82-81af-571cecb32e0d": {"__data__": {"id_": "5214b239-5dd4-4c82-81af-571cecb32e0d", "embedding": null, "metadata": {"page_label": "3", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9b36fe5b-efea-4cca-bf56-3159d8a45485", "node_type": "4", "metadata": {"page_label": "3", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "115aacedd26f7f43ea202ade894a7b5d38090d3f3513a482642a8597bca168a3", "class_name": "RelatedNodeInfo"}}, "text": "survival of both males and females was modestly enhanced in YF animals [35]. Here we report\non health impacts of enteric rapamycin treatment in YF mice of both sexes.\nMaterials and Methods\nAnimals and Husbandry\nThree month old male and female C57BL/6J mice were purchased from the Jackson Laborato-\nries. At four months of age 160 mice, 80 animals per sex, began receiving mouse chow (Purina\n5LG6) containing either microencapsulated rapamycin (14 ppm) or empty capsules\n(eudragit = control), (n = 40 animals per sex and treatment group). Animals were maintained\non their respective diets throughout life. Mice were assessed for blood levels of rapamycin at 10\nmonths (i.e. after 6 months of treatment) and began assessments for a spectrum of health pa-\nrameters starting at 16 months of age (after 12 months of treatment). All behavioral and physi-\nological assays were performed in a single-blind design at regular intervals until an animal died\nor was euthanized for health reasons. Terminally ill animals were euthanized via continued ex-\nposure to CO2 for at least 15 minutes after respiratory arrest, followed by cervical dislocation.\nUnless otherwise indicated, assessments were performed during the dark (= active) phase of\nthe 12:12 light cycle (grip strength, stride length, rotarod). Detailed descriptions of all experi-\nmental procedures may be found in our previous study of OF mice [11].\nEthics Statement\nMice were maintained under barrier conditions by the UTHSCSA Nathan Shock Center Aging\nAnimal and Longevity Assessment Core. All procedures for this study were approved by the\nInstitutional Animal Care and Use Committee at the University of Texas Health Science Cen-\nter at San Antonio. All animal died naturally or were euthanized for health reasons. All animals\nwere closely monitored by project staff daily for health; animals that showed evidence of be-\ncoming ill were checked daily until the condition resolved or the animals was euthanized. Ter-\nminally ill animals were euthanized via continued exposure to CO2 for at least 15 minutes after\nrespiratory arrest, followed by cervical dislocation.\nRapamycin Quantification\nRapamycin concentration was quantified in uncoagulated whole mouse blood using high-per-\nformance-liquid chromatography (HPLC) with tandem mass spectrometry [11]. Blood was\ncollected from both fasted and fed 10 month-old female and male mice (n = 17 and n = 14, re-\nspectively) that had been on rapamycin for 6 months.\nFood Consumption\nUsing a standard protocol [36], food consumption and body mass were measured in a subset\nof male and female, control and rapamycin-fed mice (n = 15 per sex and treatment group),\nstarting at 5 months of age until 21 months of age.\nBody Composition\nFat-free mass, fat mass and free water were measured in all animals monthly, starting at 12\nmonths of age (after 8 months of rapamycin treatment), using the EchoMRI quantitative nucle-\nar magnetic resonance system (EchoMRI 3-in-1 System, Houston, TX).\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 3/1 8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d003f25-cc6b-4003-8a6c-48655b2ab041": {"__data__": {"id_": "7d003f25-cc6b-4003-8a6c-48655b2ab041", "embedding": null, "metadata": {"page_label": "4", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7adff462-401d-4722-a64b-c281aac4c2c1", "node_type": "4", "metadata": {"page_label": "4", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "d09852c76069dec0f97a78113fd60dbf4d18b3148f41f3a42ab24577883455d0", "class_name": "RelatedNodeInfo"}}, "text": "Energetics and Spontaneous Activity\nFollowing a 12 hours acclimation period, oxygen consumption, carbon dioxide production,\ntotal metabolism and resting metabolic rate were measured over a 24-hour period using a\nMARS indirect calorimetry system (Sable Systems International, Las Vegas, NV). Spontaneous\nactivity and its temporal patterns were assessed in individually-housed animals over twenty-\nfour hours, one light and one dark phase, following a twelve hour acclimation period. Animals\nwere placed in clear, Plexiglas, (40.6 x 22.9 x 14.0 cm) cages surrounded by a 2.5 cm grid of in-\nfrared sensors in the x and y plane withad libaccess to food and water.\nMovement and Strength Parameters\nGait. Senescence induces changes in the musculoskeletal system, including many patho-\nphysiological conditions such as arthritis. Gait analysis provides a noninvasive method of as-\nsessing these changes. Gait parameters were measured using the TreadScan (Clever Sys,\nReston, VA) apparatus. Mice were started at 12 cm/s and treadmill speed was adjusted until\neach mouse maintained a consistent walking speed for 5 minutes. TreadScan uses a high-speed\ndigital camera to record reflected images of the mouse\u2019s footpads at 80 frames per second and\nthe images analyzed using mouse-specific algorithms to produce an assessment of more than\n40 gait parameters. As many of these parameters are autocorrelated, we focused on stride\nlength, which is likely to be affected by joint pain, neuromuscular deterioration and/or incipi-\nent kyphosis, as a reasonable parameter to reflect musculoskeletal health.\nRotarod. Mice were trained to use the rotarod during four sessions, spanning two weeks\nusing the protocol described in our previous study [11]. Briefly, the mouse is balanced on the\nrod and the instrument started at 4rpm with an acceleration of 0.2 rotations/second. The maxi-\nmum duration the mouse was able to balance on the rod (latency to fall) from six trials during\nthe final fifth session was used to assess rotarod performance.\nGrip strength. In humans, hand grip strength declines with increasing age and has been\nused widely as a component of frailty assessments [37]. We assessed mouse fore and hind-limb\ngrip strength using a Grip Strength Meter with mesh grid pull bar (Columbus Instruments\n1027 CSM). Mice grasped the pull bar with all four paws and were gently pulled backward in a\nhorizontal plane until they released their grip. Maximum force during each pull (= 1 trial) is re-\ncorded and the highest value from 5 consecutive trials was used as the mouse\u2019s maximum grip\nstrength for that age.\nInner Ear Histology\nDietary restriction slows the progression of age-related hearing loss in C57BL/6 mice as well as\nslowing the loss of spiral ganglion neurons and both outer and inner hair cells of the cochlea\n[38]. Because mTOR inhibition by rapamycin has been hypothesized to resemble dietary re-\nstriction [39], we examined cochlear histology at natural death in a subset of mice. Techniques\nwere those of Someya [40]. Briefly, cochleae from control (males, n = 13; females n = 18) and\nrapamycin-fed (males, n = 5; females n = 12) animals were excised from formalin-preserved\nmice, decalcified in 10% ethylenediamintetracetic acid. Paraffin-embedded sections were\nstained with haematoxylin and eosin and examined under a light microscope. Rosenthal\u2019s\ncanal was divided into three cochlear regions: apical, middle and basal, and each region was\nevaluated separately. The number of spiral ganglion neurons was counted on digital photomi-\ncrographs of each canal profile and determined as the number of neurons per mm2. Percent\nsurvival of outer hair (OH) cells was calculated as the ratio intact OH cells present relative to\nthe three OH cells normally observed in each turn of one cochlea in sections of mice with intact\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 4/1 8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0ebe0e9-c3c1-4dd4-a36c-113c9f7532e0": {"__data__": {"id_": "a0ebe0e9-c3c1-4dd4-a36c-113c9f7532e0", "embedding": null, "metadata": {"page_label": "5", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c7e54831-4721-4b3b-becb-0995300c1e35", "node_type": "4", "metadata": {"page_label": "5", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "9d4ada45e1b1635a4e5490620f40b0af2dc5a3aa595836f7d2b68c9d3c784b08", "class_name": "RelatedNodeInfo"}}, "text": "hearing. Inner hair (IH) cell survival was calculated as the number of intact IH cells compared\nto the number expected in each turn of the cochlea in tissues of mice with normal hearing.\nStatistical Methods\nThe continuous healthspan outcomes (body mass, body composition, metabolism, activity,\netc.) were analyzed using linear random-effects models (with a random intercept) to account\nfor the correlations between longitudinal measures of the same mouse. The main effects rapa-\nmycin treatment, sex, and age and their interactions were considered as potential predictors of\nhealthspan. Because the effect of age on performance could be curvilinear (e.g., on body mass),\nwe used polynomial transformations of age of up to order 3. We modeled males and females\nboth together (for greater power to detect smaller effects consistent between males and females)\nand separately if, for example, there was a significant interaction between treatment and sex.\nFor assays such as rotarod performance that are known to be affected by body size, we per-\nformed both body mass-adjusted and unadjusted analyses. The analytical computations were\nperformed using R (v2+, Vienna, Austria).\nResults\nRapamycin Blood Levels\nBlood levels of rapamycin were comparable to those measured in our previous study of C57BL/\n6 receiving enteric rapamycin started at 19 months of age and measured 6 months later (old-\nfed mice, OF) [11]. Unlike our previous results in OF mice, the YF females showed significantly\nhigher blood levels of rapamycin than YF males (Fig 1). The sex difference in rapamycin blood\nlevels of YF mice was not due to differences in food consumption, as rapamycin-fed females\ndid not consume more food per gram of body mass at testing age than did rapamycin-fed\nmales (p = 0.83). This is in contrast to our observations in old-fed mice, where OF females con-\nsumed significantly more food per gram body mass than males (p = 0.004) but showed no dif-\nferences in rapamycin levels [11]. These results are consistent with those obtained by Fok et al\n[35] in a companion study previously reported here. In this study, females also showed signifi-\ncantly higher blood levels of rapamycin than males at 10 months of age; however, rapamycin\nlevels in liver tissue measured at 25 months of age were no different between males and females\n[35]. Fok et al reported that mTOR activity in the liver, as measured by the ratio of phosphory-\nlated S6 Kinase 1 to total S6 Kinase 1, did not differ between control and rapamycin-fed ani-\nmals at 21 months of age; however, mTOR transcripts in the liver were significantly increased\nin rapamycin-fed females and a subset of the rapamycin-fed males [35].\nBody Mass and Composition\nIn both sexes and treatments, total body mass and percent fat declined progressively beginning\nat 20\u201325 months of age (Fig2A\u20132D). At 16 months of age, after one year of treatment, rapamy-\ncin-fed females weighed slightly less than controls (Treatment effect,p = 0.04) due to lower fat-\nfree mass. However, once weight loss began rapamycin-fed females lost body and fat mass sig-\nnificantly more slowly with age than controls due to a slower loss of fat (Fig2A and 2C: Treat-\nment X Age interaction,p << 0.001 in both cases). Rapamycin treated females had less fat-free\nmass than controls at all ages measured (Treatment effect,p << 0.001, Fig 2E). Fat-free mass\nalso declined significantly with age in both rapamycin-treated and control-fed females (Treat-\nment X Age interaction,p < 0.001), although this loss is obscured somewhat by the scaling in\nFig 2, which is designed to allow easy comparison between sexes. The degree of fat-free mass\nloss with age was substantially lower in rapamycin-fed females than males (Fig 2Evs 2F).\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 5/1 8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3848, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "478a69a4-5c64-496b-b17d-9640c16962a0": {"__data__": {"id_": "478a69a4-5c64-496b-b17d-9640c16962a0", "embedding": null, "metadata": {"page_label": "6", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bce6c492-eab6-4fe5-a7c0-263a4c76df20", "node_type": "4", "metadata": {"page_label": "6", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "b78c6a534b00989d2fd27e5ef84acc89c314a6d290d441ec3f2294b607d53715", "class_name": "RelatedNodeInfo"}}, "text": "Control and rapamycin-fed males did not differ in body mass or composition at 16 months\nof age, but lost mass with aging significantly differently (Treatment X Age interaction,\np < 0.001). Rapamycin-fed males began losing body mass about one month earlier than con-\ntrols (Fig 2B), although once it began to decline, mean body mass in both groups fell at similar\nrates with age such that from about 25 months of age rapamycin-fed males consistently\nweighed less than controls. For both rapamycin-fed and control males, trajectories of age-relat-\ned changes in both fat mass and fat-free mass were similar to those in total body mass.\nMetabolism and Spontaneous Activity\nA meaningful interpretation of metabolism requires accounting for body mass and composi-\ntion because fat-free mass is significantly more metabolically active than fat mass. Therefore,\nour metabolic rate measures are adjusted to amount of fat-free mass. According to this mea-\nsure, all mice showed an age-related decline in total, mass-specific metabolic rate irrespective\nFig 1. Rapamycin concentration in whole blood at 10 months of age (after 6 months of rapamycin feeding).Blood concentrations of rapamycin were\nsignificantly higher in females than males after 6 months of rapamycin feeding (n = 18 and 14 respectively).\ndoi:10.1371/journal.pone.0126644.g001\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 6/1 8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "956284ef-c6f5-4bcf-846b-dda4cd866cb5": {"__data__": {"id_": "956284ef-c6f5-4bcf-846b-dda4cd866cb5", "embedding": null, "metadata": {"page_label": "7", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "63c99209-dd7d-4863-bfb9-d159fbe4da6c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "2ca8be1964fa9fbbe4e3e76c2a6fb9775ff21560a10ac3fa1ca36dc7c5f194a9", "class_name": "RelatedNodeInfo"}}, "text": "Fig 2. Body mass and composition in rapamycin-fed mice (filled circles) versus controls (hollow circles).P-values shown on individual panels only if\nthere is a significant treatment effect independent of age. Sample sizes varied, depending on age, control females, n = 32\u20132; rapamycin females, n = 30\u20134;\ncontrol males, n = 33\u20132; rapamycin males, n = 36\u20133. A, B: Total body mass.Highly significant differences (p<< 0.001) exist in treatment x age effects in\nbody for both sexes. Although they weighed less than controls by 16 months of age, rapamycin-fed females retained body mass longer, whereas rapamycin-\nfed males were similar to controls at 16 months but lost body mass earlier and remained lighter as they aged.C, D: Percent body fat.Highly significant\ndifferences (p<< 0.001) in treatment x age effects exist for both sexes. As in with body mass, aging rapamycin-fed females retained body fat longer and lost\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 7/1 8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41336ba1-4aec-482d-899c-55fec953b60f": {"__data__": {"id_": "41336ba1-4aec-482d-899c-55fec953b60f", "embedding": null, "metadata": {"page_label": "8", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d53c4a56-25ca-4765-8555-2c6e73f1be68", "node_type": "4", "metadata": {"page_label": "8", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "4ef50474bd23b0b178aac96130ca8701fc6a74349ab34ed8244d8851b534b51e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2fd057b-6c93-4bfc-ad5f-68e11eddeba5", "node_type": "1", "metadata": {}, "hash": "cac64fc1f6b50161af3125d09467cd0376ef1212e45515625c2479f46dd0abec", "class_name": "RelatedNodeInfo"}}, "text": "of sex or treatment from about 20 months of age (Age effect,p << 0.001 in all cases). In fe-\nmales, there was no significant effect of rapamycin treatment during the light (= inactive)\nphase of the 24 hour light:dark cycle (Fig 3A), but rapamycin-fed females exhibited highertotal\nmass-specific metabolic rate during the dark (i.e., active) phase (Fig 3C: Treatment effect,\np = 0.003) and a higher mass-specificresting metabolic rate (Fig 3E: Treatment effect,p = 0.01)\nirrespective of light:dark cycle.\nBy contrast, males showed no differences in total metabolic rate as a function of treatment in\neither phase of the 24 hour light:dark cycle. Interestingly, control males showed no decline in\nrestingmetabolic rate with age, whereas it declined significantly in the rapamycin-fed group (Fig\n3F), thus there was a highly significant Treatment X Age interaction (p << 0.001) in males.\nTotal spontaneous activity over 24 hours was statistically greater in females than males (Fig\n4A vs 4B, Sex effect, p<<0.001). Surprisingly, spontaneous activity as we measured it increased\nwith age in females (Age effect, p = 0.008) but decreased as expected in males (Age effect,\np = 0.003). Rapamycin feeding had no impact on total activity in females (Treatment effect,\np = 0.54) or males (Treatment effect,p = 0.39).\nTemporal patterns of sleep were monitored by analyzing bouts of inactivity greater than 40\nseconds in length as previously validated for male C57BL/6 mice [11, 41]. Using this metric, fe-\nmales, but not males, slept less as they aged (Fig 4C, Age effect,p << 0.001). Rapamycin-feed-\ning resulted in a marginally significant increase in total sleep time (Treatment effect,p = 0.05)\nwhen the sexes were combined, but not when each sex was treated separately (females: Treat-\nment effect,p = 0.10, males: Treatment effect,p = 0.26). Sleep fragmentation, as assessed by the\nnumber of sleep bouts per hour of sleep, increased with age in all animals (Fig4E and 4F, Age\neffect, p << 0.001) as has been previously reported for both humans and mice. However, con-\nsistent with our OF results, rapamycin treatment reduced sleep fragmentation in males relative\nto controls (Treatment effect,p= 0.03). Unlike our OF results, rapamycin treatment reduced\nsleep fragmentation marginally in females (Treatment effect,p = 0.06) compared to controls.\nBecause this high-throughput sleep assessment protocol has only been validated in C57BL/6\nmales, the above results for females should be interpreted with caution.\nStrength and Movement\nAs in humans, mouse grip strength declined with age in both male and female mice (Fig5A and\n5B, Age effect,p << 0.001). As with a number of other parameters, rapamycin-feeding had a\nsex-specific effect. Rapamycin-fed females\u2019grip was stronger than that of female controls at all\nages measured (Treatment effect,p = 0.005), whereas grip strength of control and rapamycin-fed\nmales did not differ (Treatment effect,p = 0.21). Although there were sex- and treatment-specific\ndifferences in body mass, these did not explain the grip strength results as body mass did not cor-\nrelate with grip strength in either male (r2 =0 . 0 7 ,p = 0.07) or female mice (r2 =0 . 0 1 ,p =0 . 9 0 ) .\nStride length has previously been reported to decline with age in C57BL/6 mice [11, 42]. In\nboth sexes stride length actuallyincreased until 27 months of age, after which it declined with\nincreasing age (Fig5C and 5D, Age effect,p << 0.001). However, rapamycin treatment had no\neffect on age-related changes in stride length in either sex (Treatment X Age effect, females:\np= 0.88, males:p = 0.48).\nRotarod performance in mice is well known to be strongly affected by body mass [11, 43,\n44] as it was in this study (Mass effect,p < 0.001 for both sexes). Therefore, we used body mass\nbody fat more slowly than age-matched controls.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2fd057b-6c93-4bfc-ad5f-68e11eddeba5": {"__data__": {"id_": "d2fd057b-6c93-4bfc-ad5f-68e11eddeba5", "embedding": null, "metadata": {"page_label": "8", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d53c4a56-25ca-4765-8555-2c6e73f1be68", "node_type": "4", "metadata": {"page_label": "8", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "4ef50474bd23b0b178aac96130ca8701fc6a74349ab34ed8244d8851b534b51e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41336ba1-4aec-482d-899c-55fec953b60f", "node_type": "1", "metadata": {"page_label": "8", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "6ef749fb012cca5cd1ca1db63b4a42e5090d55b91bb7f465cf590e9abbd261e4", "class_name": "RelatedNodeInfo"}}, "text": "0 1 ,p =0 . 9 0 ) .\nStride length has previously been reported to decline with age in C57BL/6 mice [11, 42]. In\nboth sexes stride length actuallyincreased until 27 months of age, after which it declined with\nincreasing age (Fig5C and 5D, Age effect,p << 0.001). However, rapamycin treatment had no\neffect on age-related changes in stride length in either sex (Treatment X Age effect, females:\np= 0.88, males:p = 0.48).\nRotarod performance in mice is well known to be strongly affected by body mass [11, 43,\n44] as it was in this study (Mass effect,p < 0.001 for both sexes). Therefore, we used body mass\nbody fat more slowly than age-matched controls. In contrast, rapamycin-fed males initially had a higher percentage of body fat, but lost fat mass earlier than\ncontrols. E, F: Fat-free mass, sometimes referred to as lean mass. Although obscured by the scaling, rapamycin-fed females had lower fat-free mass than\ncontrols at all ages measured. Fat-free mass declined more slowly with age in rapamycin-fed females than males.\ndoi:10.1371/journal.pone.0126644.g002\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 8/1 8", "mimetype": "text/plain", "start_char_idx": 3187, "end_char_idx": 4362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39723756-c275-4326-b9ab-e6506069209e": {"__data__": {"id_": "39723756-c275-4326-b9ab-e6506069209e", "embedding": null, "metadata": {"page_label": "9", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cc99e29d-03d8-4cdf-9d55-2978558f6e74", "node_type": "4", "metadata": {"page_label": "9", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "cfe853adc41ec0ec99921fc8dfbe856534c386cccf398c7bdfce8dcaf992a124", "class_name": "RelatedNodeInfo"}}, "text": "Fig 3. Metabolic activity in rapamycin-fed mice (filled circles) compared to controls (hollow circles).P-values shown on individual panels only if there\nis a significant treatment effect independent of age. Sample sizes varied, depending on age, control females, n = 8\u20134; rapamycin females, n = 11\u20133; control\nmales, n = 9\u20135; rapamycin males, n = 16\u20132. A, B: Mass-specific metabolic rate during the light (= inactive) phase. Males and females showed no effects\nof rapamycin treatment on mass-specific metabolic rate during the inactive phase of their daily 24-hour cycle, although both sexes showed highly significant\n(p << 0.001) sex x age treatment effects.C, D: Mass-specific metabolic rate during the dark (= active) phase. Aging rapamycin-fed females, but not\nmales, maintained significantly higher metabolic rates between measures taken at 24 and 28 months of age compared to controls during the dark (= active)\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 9/1 8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1027, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a2d691b-a8ae-4891-b3d7-f9b9b49ae8c9": {"__data__": {"id_": "9a2d691b-a8ae-4891-b3d7-f9b9b49ae8c9", "embedding": null, "metadata": {"page_label": "10", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c75c254d-cbe8-4556-9976-a83caa83d43f", "node_type": "4", "metadata": {"page_label": "10", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "ab6ba3861358547bb4aee73172a98568aa519cd3b43554594d526b846925eb5d", "class_name": "RelatedNodeInfo"}}, "text": "as a covariate in our analysis. There was no clear pattern of change with age in either females\n(Fig 5E) or males (Fig 5F). Rapamycin treatment had no effect on female performance (Treat-\nment effect,p = 0.42), but had a marginally significant negative effect on male rotarod perfor-\nmance (Treatment effect,p = 0.06). If body mass was ignored, there was still no rapamycin\neffect in females (Treatment effect,p = 0.65) and a significant negative effect in males (Treat-\nment effect,p = 0.01).\nCochlear Histology\nAge-related hearing loss is a common feature of aging and associated with loss of spiral gangli-\non neurons and sensory inner and outer hair cells in the cochlea. Cochlear histology in rapa-\nmycin-treated and control mice was assessed upon natural death or health-related euthanasia.\nThere were no statistically significant differences in the ages of animals of either sex examined\nas a function of treatment (Mann-Whitney Rank Sum Test: males:p = 0.63, females:p = 0.45).\nMedian ages examined were 24.4 and 25.4 months for control and rapamycin-fed males, re-\nspectively, and 24.5 and 25.5 months form control and rapamycin-fed females. No statistical\ndifferences between rapamycin-fed and control mice were observed (Fig 6). Collectively, rapa-\nmycin treatment had no impact on age-related cochlear pathology in males or females.\nDiscussion\nThis study administered enteric rapamycin to C57BL/6J mice of both sexes andlongitudinally\nmonitored their phenotypes for a longer time\u2014 from 4 months of age until death\u2014 than any\nprevious study. Therefore, individual, life-long trajectories of phenotypic change could be ana-\nlyzed. Although survival was increased in both sexes [35], only some presumptive metrics of\nhealth were improved (female grip strength, reduced sleep fragmentation, body mass), a num-\nber showed no significant change, and at least one (male rotarod performance) was negatively\naffected. Age-related improvements in total sleep and greater sleep consolidation with rapamy-\ncin-feeding were observed in both sexes here, this is contrast to our previous OF study where\nonly rapamycin treated males showed improvements in sleep [11]. These are the first reports of\nrapamycin affecting sleep.\nAt least 7 previous studies in an array of genotypes have reported enhanced longevity in mice\nadministered rapamycin [2, 3, 5, 11, 15, 21, 45]. However, reports of rapamycin\u2019se f f e c t so n\nhealth have been less numerous, none have made repeated assessments of the same animals lon-\ngitudinally, and results have been considerably less uniform than the survival results. The health\neffects described here differ from those reported in our own previous study\u2014 performed in the\nsame facility with the same equipment. Compared to our previous study, in which enteric rapa-\nmycin treatment was initiated at 19 months and continued throughout life (OF mice) [11], the\nYF mice in this study exhibited considerable differences in phenotype, and not just in the ex-\npected direction one might associate with earlier age and longer duration of rapamycin treatment\n(Table 1). For instance, we previously found rapamycin feeding significantly decreased mass-spe-\ncific food consumption and resting metabolic rate in OF females relative to controls [11]. By con-\ntrast, YF females showed no difference in mass-specific food consumption and anincreased\nresting metabolic rate compared to controls (Table 1). The pattern of age-related body mass and\ncomposition changes also differs between the two studies. In OF females, there was no significant\nphase of the 24-hour light cycle. Both males and females showed highly significant (p<<0.001) decline dark-phase metabolic rate with age irrespective of\ntreatment. E, F: Resting mass-specific metabolic rate. Resting metabolic rate declined with age in females, but aging rapamycin-fed females had higher\nresting metabolic rates compared to age-matched controls. Resting metabolic rate declined significantly in aging rapamycin-fed males but not in age-\nmatched controls (treatment x age, p<< 0.001).\ndoi:10.1371/journal.pone.0126644.g003\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 10 / 18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cd0d83a-094b-4b50-92eb-580cd03b4585": {"__data__": {"id_": "4cd0d83a-094b-4b50-92eb-580cd03b4585", "embedding": null, "metadata": {"page_label": "11", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "043f045f-3980-45ea-b870-2b2b83c018f4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "ff0c50bdd03af133ecbecf5713d06f7bab771040447e7e77283607cefb1c0dbe", "class_name": "RelatedNodeInfo"}}, "text": "Fig 4. Spontaneous activity and sleep in rapamycin-fed mice (filled circles) compared to controls (hollow circles).P-values shown on individual\npanels only if there is a significant treatment effect independent of age. Sample sizes varied, depending on age, control females, n = 14\u20132; rapamycin\nfemales, n = 18\u20135; control males, n = 13\u20134; rapamycin males, n = 22\u20137. A, B: Spontaneous 24-hour activitywas greater in females than males (p<<\n0.001). Activity increased with age (p = 0.008) in females and decreased with age in males (p = 0.003), regardless of treatment.C, D: Total sleepRapamycin\ntreatment marginally increased total sleep in both sexes (p = 0.05) when taken together, but aging affected sleep patterns in the two sexes differently (age x\nsex, p<< 0.001). E, F: Sleep fragmentationincreased with age in all animals (p<< 0.001); however, rapamycin treatment reduced sleep fragmentation in\nmales and showed a trend to reduce it in females.\ndoi:10.1371/journal.pone.0126644.g004\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 11 / 18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b40e3edc-bf1f-4bcf-be52-7fa01a44a1aa": {"__data__": {"id_": "b40e3edc-bf1f-4bcf-be52-7fa01a44a1aa", "embedding": null, "metadata": {"page_label": "12", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c90146e-501d-474d-9c7f-ab57b5351320", "node_type": "4", "metadata": {"page_label": "12", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "bd284664c3876a5fbdce61884832e83878ec2effaa04213d6b6557f98792cc99", "class_name": "RelatedNodeInfo"}}, "text": "Fig 5. Strength, coordination and movement in rapamycin-fed mice (filled circles) compared to controls (hollow circles).P-values shown on\nindividual panels only if there is a significant treatment effect independent of age.A, B: Grip strengthdeclined significantly with age in all animals, regardless\nof treatment (p<< 0.001); however rapamycin treatment affected males and females differently (treatment x sex, p = 0.003). Rapamycin-fed females had\ngreater grip strength than controls at all ages measured; whereas grip strength in control and rapamycin treated males did not differ. Sample sizes varied,\ndepending on age, control females, n = 17\u20137; rapamycin females, n = 27\u20134; control males, n = 22\u20134; rapamycin males, n = 31\u20133. C, D: Stride length\nincreased in males and females until 27 months of age and then declined with increasing age (p<< 0.001). Rapamycin treatment had no effect on stride\nlength in either sex. Sample sizes varied, depending on age, control females, n = 15\u20136; rapamycin females, n = 21\u20135; control males, n = 19\u20134; rapamycin\nmales, n = 26\u20139. E, F: Rotarod performance, measured as maximum latency to fall, was significantly affected by body mass (p<< 0.001) and so body mass\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 12 / 18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd9e472e-6a71-49d4-a183-96702490dcb1": {"__data__": {"id_": "cd9e472e-6a71-49d4-a183-96702490dcb1", "embedding": null, "metadata": {"page_label": "13", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "34644c3f-64c6-4384-9204-059621682d40", "node_type": "4", "metadata": {"page_label": "13", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "3073f938fe5a37ad96cabf2e2e0e1505f387dd2865c3d879b45132bdd4d93ef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99b5201a-d4cf-4958-8043-462c16b34097", "node_type": "1", "metadata": {}, "hash": "4d92b769a127dc860325205b10d0b78d718e921515c7805fc569ba217ed8182d", "class_name": "RelatedNodeInfo"}}, "text": "difference in total body mass, percent body fat, or their rate of decline with age compared with\ncontrols; however YF females were significantly better than controls at maintaining body and fat\nmass into late life (Fig 2). Given its well-known role in growth and previous, shorter-term studies\nof its effects on body mass [3, 21, 45], the better maintenance of body and fat mass with age in\nour YF females was a substantial surprise. OF females showed no difference in fat-free mass com-\npared with controls, whereas YF females had less fat-free mass than controls. Thus, the impact of\nrapamycin-feeding on various metabolic parametersin femalesappears to depend on the age of\ninitiation and/or the duration of feeding in sometimes counterintuitive ways.\nOF and YF male phenotypic changes also differed in response to rapamycin treatment, but\nmainly in easily understood directions. Several parameters such as percent body fat or mass-\nspecific food consumption that did not achieve statistical significance in the shorter duration,\nOF study, did achieve significance in the longer, YF study. Unlike the current study, there was\nno statistically significant difference between the sexes in blood concentration of rapamycin in\nthe OF study. However, both studies showed differences in the same direction, with females\nshowing higher blood levels of rapamycin than males.\nSex-specific phenotypic effects of enteric rapamycin treatment in mice have been widely re-\nported; in this study we report sex differences in thedirection of phenotypic change. While\nmales and females on enteric rapamycin were both significantly different from controls, they\nexhibited changes in the opposite direction in measures of body mass, percent fat and mass-\nspecific resting metabolic rate. While this pattern of sex differences has not been previously re-\nported, few phenotypic studies have been performed on both sexes (although see [15, 45]) and\nnone have been performed longitudinally in both sexes over as long a time course as the pres-\nent study. In the few phenotypic studies of both sexes that have been reported, it is not uncom-\nmon to find a statistically significant difference associated with enteric rapamycin treatment in\none sex but not the other. Both this study and Miller, et al. [45] found significantly greater\nblood concentrations of rapamycin in females compared with males. In this study, the pattern\nwas not a result of greater mass-specific food consumption in females, suggesting that such dif-\nferences could be a consequence of greater bioavailability of rapamycin in females compared\nwith males. Still, interpretation of differences in blood concentration should be treated with\ncaution as they do not necessarily reflect tissue concentration of rapamycin [11, 35]. The mech-\nanistic basis of these sex-specific differences certainly warrants further study.\nA number of studies have previously reported health effects of rapamycin administration in\nshorter-term experiments. For instance, rapamycin treatment by injection in 22\u201324 month old\nmale C57BL/6 mice improved several measures of health, including hematopoietic stem cell\nfunction [5] and 3 months of enteric rapamycin treatment in even older female C57BL/6 mice\nimproved cardiac function and some metrics of behavioral, motor and skeletal phenotypes [1].\nSimilarly, chronically administered enteric rapamycin started at 9 months of age at a range of\ndoses (4.7\u201342 ppm) maintained activity and blunted the expression of aging-related changes in\nheart, liver, adrenal glands, endometrial tissue and tendons in 20\u201322 month-old male and fe-\nmale UM-HET3 mice [15]. Likewise, chronic, enteric rapamycin treatment enhanced cognitive\nfunction in young C57BL/6 adult mice and reduced age-associated cognitive decline in older\nmice of both sexes [20] and Neff et al. [21] reported improved hepatic, immune and endocrine\nfunction in male mice of the same strain.\nwas included as a covariate in the analysis. With the effects of body size removed, females showed no effects of rapamycin treatment and males showed a\nmarginally significant negative effect of rapamycin treatment on rotarod performance. The y-axis shows the residuals of rotarod performance (latency to fall)\nregressed against body mass. Sample sizes varied, depending on age, control females, n = 11\u20136; rapamycin females, n = 19\u20136; control males, n = 13\u20137;\nrapamycin males, n = 21\u20138.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99b5201a-d4cf-4958-8043-462c16b34097": {"__data__": {"id_": "99b5201a-d4cf-4958-8043-462c16b34097", "embedding": null, "metadata": {"page_label": "13", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "34644c3f-64c6-4384-9204-059621682d40", "node_type": "4", "metadata": {"page_label": "13", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "3073f938fe5a37ad96cabf2e2e0e1505f387dd2865c3d879b45132bdd4d93ef5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd9e472e-6a71-49d4-a183-96702490dcb1", "node_type": "1", "metadata": {"page_label": "13", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "e2c7f835ce4d64beb22a4f4b33cd1c75aa7a945859c5d56a8b7f7aba8d2519bc", "class_name": "RelatedNodeInfo"}}, "text": "Likewise, chronic, enteric rapamycin treatment enhanced cognitive\nfunction in young C57BL/6 adult mice and reduced age-associated cognitive decline in older\nmice of both sexes [20] and Neff et al. [21] reported improved hepatic, immune and endocrine\nfunction in male mice of the same strain.\nwas included as a covariate in the analysis. With the effects of body size removed, females showed no effects of rapamycin treatment and males showed a\nmarginally significant negative effect of rapamycin treatment on rotarod performance. The y-axis shows the residuals of rotarod performance (latency to fall)\nregressed against body mass. Sample sizes varied, depending on age, control females, n = 11\u20136; rapamycin females, n = 19\u20136; control males, n = 13\u20137;\nrapamycin males, n = 21\u20138.\ndoi:10.1371/journal.pone.0126644.g005\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 13 / 18", "mimetype": "text/plain", "start_char_idx": 3633, "end_char_idx": 4561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "887857b5-bae5-44a5-9087-6a2a6db068cb": {"__data__": {"id_": "887857b5-bae5-44a5-9087-6a2a6db068cb", "embedding": null, "metadata": {"page_label": "14", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f4bd806b-ad5e-4419-adc6-54afc3be9944", "node_type": "4", "metadata": {"page_label": "14", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "38a6018dedf1d4a78c3772406f0937ff38f171b43eb215ca46aaa6e7a345c32d", "class_name": "RelatedNodeInfo"}}, "text": "Conclusions\nIn sum, longitudinal measures of health in C57BL/6J mice treated with enteric rapamycin\n(14 ppm) from 4 months of age revealed a number of previously unreported patterns. Although\nFig 6. Age-related changes in inner ear histology was not altered by rapamycin treatment. A, B: The number of cochlear neuronsin male and\nfemale mice were not statistically different between control and rapamycin-fed animals.C,D: The number of outer hair cellsin male and female mice were\nnot statistically different between control and rapamycin-fed animals.E,F: The number of inner hair cellsin male and female mice were not statistically\ndifferent between control and rapamycin-fed animals.\ndoi:10.1371/journal.pone.0126644.g006\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 14 / 18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bae3a263-131c-4c30-a959-d2c6be021046": {"__data__": {"id_": "bae3a263-131c-4c30-a959-d2c6be021046", "embedding": null, "metadata": {"page_label": "15", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "42955d0f-bba4-4584-a384-663bd0842e1c", "node_type": "4", "metadata": {"page_label": "15", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "3caed54db1dd2da1f1a5fb0b0cb6b5a1b297b3e51851e0494f66f0ac19b688d4", "class_name": "RelatedNodeInfo"}}, "text": "a number of health parameters were improved and a number unchanged, at least one (male\nrotarod performance) was marginally worse under rapamycin treatment. Other deleterious\nside effects including testicular atrophy, accelerated cataract formation, and glucose insensitivi-\nty have been reported in shorter-term (~1 year) rapamycin feeding studies [15, 45]. Whether\nsome of these effects, such as glucose insensitivity abate with longer-term treatment remains\nan intriguing question. We also observed considerable sex-specificity in the effects of enteric\nrapamycin treatment, including not only significant effects in one sex that were absent from\nthe other, but also opposite phenotypic effects between the sexes. This phenomenon may pro-\nvide insights into mechanisms underlying sex differences in aging and deserves further inquiry.\nAcknowledgments\nJohn Ramos, Vivian Diaz and the staff at the Barshop Institute provided exemplary animal\ncare that made this study possible. Dr. Alex Bokov offered expert advice on analytical issues.\nProf. Walter Ward and Vivian Diaz provided data on food consumption; Drs. Lauren Sloane\nand Steven Treaster, and Samantha Rendon and Keith Maslin assisted with data collection;\nProf. Martin Javors analyzed blood levels of rapamycin. Logan K. Walker assisted with cochlear\nneuron counting. We thank the editor and an anonymous reviewer for their helpful sugges-\ntions. Figures were prepared using Scientifig (https://grr.gred-clermont.fr/labmirouse/\nsoftware/index.html)[ 46].\nTable 1. Differences in two rapamycin studies.\nC57BL/6 responses to rapamycin 14ppm\nMeasure Young-fed Old-fed\nFemale Male Female Male\nFat-free mass #*** #***\u00a7 \u2014 #*\u00a7\nTotal body mass \"***\u00a7 #***\u00a7 \u2014 \"#***\u00a7\nPercent fat \"***\u00a7 #***\u00a7 \u2014\u2014\nMass-speci\ufb01c Food Consumption \u2014 \"**\u00a7 #** \u2014\nLight phase O2 consumption \u2014\u2014 #* \u2014\nDark phase O2 consumption \"** \u2014\u2014 \u2014\nResting Metabolic Rate \"* #***\u00a7 #** \u2014\nTotal activity (24h) \u2014\u2014 \u2014\u2014\nTotal sleep \"* \"* \u2014\u2014\nSleep fragmentation #** #** \u2014 #**\nGrip strength \"** \u2014\u2014 \u2014\nRotarod performance \u2014 #\" * \"*\nStride length \u2014\u2014 \"#** \"#**\nSurvival \"** \"* \"** \"**\n\" Increased # Decreased, \"# Maintained with age,\u2014 No difference from controls\n*p < 0.05\n** p < 0.01\n*** p < 0.001\n\u00a7 Treatment X Age effect\nHealthspan measures: young-fed measured between ages 16 and 29 months; old-fed measured at 25, 31 and 32 months.\nYoung-fed mice (rapamycin feeding begun at 4 mo, this study) compared with old-fed (rapamycin feeding begun at 19 mo) [11].\ndoi:10.1371/journal.pone.0126644.t001\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 15 / 18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "252914df-5a2c-47ad-9c29-ba7e7b11f2c7": {"__data__": {"id_": "252914df-5a2c-47ad-9c29-ba7e7b11f2c7", "embedding": null, "metadata": {"page_label": "16", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3a90324c-72d1-4b69-94a0-80ddaf24396c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "a5079af7565c72d83fbf87c661f1b73bf6d014988ea766f12ebc34a1ed867086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a6a0552-3563-4734-923e-6f7e02e6b9cb", "node_type": "1", "metadata": {}, "hash": "5718b2b4b81f43cb961a5ccb6a19d3e1da9d63d2cd37d77ba9a9257ed4db1371", "class_name": "RelatedNodeInfo"}}, "text": "Author Contributions\nConceived and designed the experiments: KEF AR SNA. Performed the experiments: KEF VYS\nSS CH. Analyzed the data: KEF JALG SNA. Contributed reagents/materials/analysis tools:\nJALG SS. Wrote the paper: KEF SNA JALG. Revised manuscript: VYS AR SS CH.\nReferences\n1. Flynn JM, O'Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, et al. Late-life rapamycin\ntreatment reverses age-related heart dysfunction. Aging Cell. 2013; 12(5):851\u201362. doi:10.1111/acel.\n12109 PMID: 23734717.\n2. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life ex-\ntends lifespan in genetically heterogeneous mice. Nature. 2009; 460(7253):392\u20135. doi:10.1038/\nnature08221 PMID: 19587680\n3. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de CR, et al. Rapamycin, but not resveratrol or\nsimvastatin, extends life span of genetically heterogeneous mice. JGerontolA BiolSciMedSci. 2011; 66\n(2):191\u2013201. doi: glq178 [pii];doi:10.1093/gerona/glq178\n4. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al.\nRapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell\nCycle. 2011; 10(24):4230\u20136. doi: 18486 [pii];doi:10.4161/cc.10.24.18486 PMID: 22107964\n5. Chen C, Liu Y, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic\nstem cells. SciSignal. 2009; 2(98):ra75.\n6. Medvedik O, Lamming DW, Kim KD, Sinclair DA. MSN2 and MSN4 link calorie restriction and TOR to\nsirtuin-mediated lifespan extension in Saccharomyces cerevisiae. PLoS Biol. 2007; 5(10):e261. doi:\n06-PLBI-RA-0346 [pii];doi:10.1371/journal.pbio.0050261 PMID: 17914901\n7. Powers RW III, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span\nin yeast by decreased TOR pathway signaling. Genes Dev. 2006; 20(2):174\u201384. PMID:16418483\n8. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, et al. With TOR, less is more: a key\nrole for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 2010; 11(6):453\u201365. doi:\nS1550-4131(10)00153-1 [pii];doi:10.1016/j.cmet.2010.05.001 PMID: 20519118\n9. Kaeberlein M, Powers RW III, Steffen KK, Westman EA, Hu D, Dang N, et al. Regulation of yeast repli-\ncative life span by TOR and Sch9 in response to nutrients. Science. 2005; 310(5751):1193\u20136. PMID:\n16293764\n10. Katewa SD, Kapahi P. Role of TOR signaling in aging and related biological processes in Drosophila\nmelanogaster. Experimental gerontology. 2011; 46(5):382\u201390. Epub 2010/12/07. doi:10.1016/j.exger.\n2010.11.036 PMID: 21130151; PubMed Central PMCID: PMCPmc3058120.\n11. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a6a0552-3563-4734-923e-6f7e02e6b9cb": {"__data__": {"id_": "0a6a0552-3563-4734-923e-6f7e02e6b9cb", "embedding": null, "metadata": {"page_label": "16", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3a90324c-72d1-4b69-94a0-80ddaf24396c", "node_type": "4", "metadata": {"page_label": "16", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "a5079af7565c72d83fbf87c661f1b73bf6d014988ea766f12ebc34a1ed867086", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "252914df-5a2c-47ad-9c29-ba7e7b11f2c7", "node_type": "1", "metadata": {"page_label": "16", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "f3cc69bd964dc6750ab5b91663c1f4c40fad441354c20215a78d609fd7da7aa3", "class_name": "RelatedNodeInfo"}}, "text": "Regulation of yeast repli-\ncative life span by TOR and Sch9 in response to nutrients. Science. 2005; 310(5751):1193\u20136. PMID:\n16293764\n10. Katewa SD, Kapahi P. Role of TOR signaling in aging and related biological processes in Drosophila\nmelanogaster. Experimental gerontology. 2011; 46(5):382\u201390. Epub 2010/12/07. doi:10.1016/j.exger.\n2010.11.036 PMID: 21130151; PubMed Central PMCID: PMCPmc3058120.\n11. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, et al. Rapamycin extends life and health in\nC57BL/6 mice. The journals of gerontology Series A, Biological sciences and medical sciences. 2014;\n69(2):119\u201330. doi:10.1093/gerona/glt056 PMID: 23682161; PubMed Central PMCID: PMC4038246.\n12. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124(3):471\u2013\n84. doi: S0092-8674(06)00108-5 [pii];doi:10.1016/j.cell.2006.01.016 PMID: 16469695\n13. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian\ntarget of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. JBiolChem.\n2010; 285(17):13107\u201320. doi: M110.100420 [pii];doi:10.1074/jbc.M110.100420 PMID: 20178983\n14. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by\nrapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzhei-\nmer's disease. PLoSOne. 2010; 5(4):e9979. doi:10.1371/journal.pone.0009979 PMID: 20376313\n15. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, et al. Rapamycin slows\naging in mice. Aging Cell. 2012; 11(4):675\u201382. doi:10.1111/j.1474-9726.2012.00832.x PMID:\n22587563\n16. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, et al.\nRapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012; 4\n(10):709\u201314. Epub 2012/11/06. PMID:23123616; PubMed Central PMCID: PMCPmc3517941.\n17. Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, et al. Rapamycin extends life span\nof Rb1+/- mice by inhibiting neuroendocrine tumors. Aging. 2013; 5(2):100\u201310. PMID:23454836;\nPubMed Central PMCID: PMC3616197.\n18. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque\nprogression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardio-\nvascPharmacol. 2005; 46(4):481\u20136. PMID:16160601\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 16 / 18", "mimetype": "text/plain", "start_char_idx": 2221, "end_char_idx": 4740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2398bac3-473e-4e4b-bbd8-9fc37c331e49": {"__data__": {"id_": "2398bac3-473e-4e4b-bbd8-9fc37c331e49", "embedding": null, "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4883ada8-3e80-4878-960d-f711f276cea5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "1ea26f987c168c3db7bfd1d1da7cbf138b4047d74eca53a8a90867291b8fe3c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b011f2c-8d09-41fb-993e-f3f3c0d71e17", "node_type": "1", "metadata": {}, "hash": "f36fa8e7b70338d15febf90f53427dc8b199574d975f32f6ef512edfddbf7c60", "class_name": "RelatedNodeInfo"}}, "text": "19. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, et al. Lifelong rapamycin ad-\nministration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA\nsignaling. Aging Cell. 2011. doi:10.1111/j.1474-9726.2011.00791.x\n20. Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, et al. Chronic inhibition of\nmammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of\nbehavior throughout lifespan in mice. Neuroscience. 2012; 223C:102\u201313. doi: S0306-4522(12)00672-0\n[pii];doi: 10.1016/j.neuroscience.2012.06.054\n21. Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, et al. Rapamycin extends mu-\nrine lifespan but has limited effects on aging. The Journal of clinical investigation. 2013; 123(8):3272\u2013\n91. Epub 2013/07/19. doi:10.1172/jci67674 PMID: 23863708; PubMed Central PMCID:\nPMCPmc3726163.\n22. Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, Spong A, et al. Duration of rapamycin treatment has\ndifferential effects on metabolism in mice. Cell Metab. 2013; 17(3):456\u201362. doi:10.1016/j.cmet.2013.\n02.008 PMID: 23473038; PubMed Central PMCID: PMC3658445.\n23. Spong A, Bartke A. Rapamycin slows aging in mice. Cell Cycle. 2012; 11(5):845. Epub 2012/02/24.\ndoi: 10.4161/cc.11.5.19607 PMID: 22356747.\n24. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. Rapamycin-induced in-\nsulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012; 335\n(6076):1638\u201343. doi: 335/6076/1638 [pii];doi:10.1126/science.1215135 PMID: 22461615\n25. Lamming DW, Ye L, Astle CM, Baur JA, Sabatini DM, Harrison DE. Young and old genetically hetero-\ngeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. Aging Cell. 2013;\n12(4):712\u20138. doi:10.1111/acel.12097 PMID: 23648089; PubMed Central PMCID: PMC3727050.\n26. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: efficacy, side effects, and\nutilization. PediatrClinNorth Am. 2003; 50(6):1283\u2013300. PMID:14710781\n27. Welzl K, Kern G, Mayer G, Weinberger B, Saemann MD, Sturm G, et al. Effect of different immunosup-\npressive drugs on immune cells from young and old healthy persons. Gerontology. 2014; 60(3):229\u2013\n38. Epub 2014/01/18. doi:10.1159/000356020 PMID: 24434865.\n28. Hinojosa CA, Mgbemena V, Van RS, Austad SN, Miller RA, Bose S, et al. Enteric-delivered rapamycin\nenhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence.\nExpGerontol. 2012; 47(12):958\u201365. doi: S0531-5565(12)00250-1 [pii];doi:10.1016/j.exger.2012.08.\n013 PMID: 22981852\n29.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b011f2c-8d09-41fb-993e-f3f3c0d71e17": {"__data__": {"id_": "4b011f2c-8d09-41fb-993e-f3f3c0d71e17", "embedding": null, "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4883ada8-3e80-4878-960d-f711f276cea5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "1ea26f987c168c3db7bfd1d1da7cbf138b4047d74eca53a8a90867291b8fe3c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2398bac3-473e-4e4b-bbd8-9fc37c331e49", "node_type": "1", "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "6b0dde24d6ff645a1d7188af8a0b3ef051814abcdb49daa76c8295f1f60e8ef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "005d32e3-5583-4585-86d2-7ca38a37a851", "node_type": "1", "metadata": {}, "hash": "cf5757e94b407d5af8abc3aada6eb40537ea3794f29a79f7db629045812489ab", "class_name": "RelatedNodeInfo"}}, "text": "Effect of different immunosup-\npressive drugs on immune cells from young and old healthy persons. Gerontology. 2014; 60(3):229\u2013\n38. Epub 2014/01/18. doi:10.1159/000356020 PMID: 24434865.\n28. Hinojosa CA, Mgbemena V, Van RS, Austad SN, Miller RA, Bose S, et al. Enteric-delivered rapamycin\nenhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence.\nExpGerontol. 2012; 47(12):958\u201365. doi: S0531-5565(12)00250-1 [pii];doi:10.1016/j.exger.2012.08.\n013 PMID: 22981852\n29. Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, et al. Sirolimus enhances the\nmagnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus\nmacaques. American journal of transplantation: official journal of the American Society of Transplanta-\ntion and the American Society of Transplant Surgeons. 2011; 11(3):613\u20138. Epub 2011/02/24. doi:10.\n1111/j.1600-6143.2010.03407.x PMID: 21342450; PubMed Central PMCID: PMCPmc3076606.\n30. Dickinson JM, Fry CS, Drummond MJ, Gundermann DM, Walker DK, Glynn EL, et al. Mammalian tar-\nget of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein\nsynthesis by essential amino acids. JNutr. 2011; 141(5):856\u201362. doi: jn.111.139485 [pii];doi:10.3945/\njn.111.139485 PMID: 21430254\n31. Aoyagi T, Kusakari Y, Xiao CY, Inouye BT, Takahashi M, Scherrer-Crosbie M, et al. Cardiac mTOR pro-\ntects the heart against ischemia-reperfusion injury. AmJPhysiol Heart CircPhysiol. 2012; 303(1):H75\u2013\nH85. doi: ajpheart.00241.2012 [pii];doi:10.1152/ajpheart.00241.2012 PMID: 22561297\n32. Stoica L, Zhu PJ, Huang W, Zhou H, Kozma SC, Costa-Mattioli M. Selective pharmacogenetic inhibition\nof mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and mem-\nory storage. ProcNatlAcadSciUSA. 2011; 108(9):3791\u20136. doi: 1014715108 [pii];doi:10.1073/pnas.\n1014715108 PMID: 21307309\n33. Parsons RG, Gafford GM, Helmstetter FJ. Translational control via the mammalian target of rapamycin\npathway is critical for the formation and stability of long-term fear memory in amygdala neurons. JNeur-\nosci. 2006; 26(50):12977\u201383. doi: 26/50/12977 [pii];doi:10.1523/JNEUROSCI.4209-06.2006 PMID:\n17167087\n34. Larsen JL, Bennett RG, Burkman T, Ramirez AL, Yamamoto S, Gulizia J, et al. Tacrolimus and siroli-\nmus cause insulin resistance in normal sprague dawley rats. Transplantation. 2006; 82(4):466\u201370. doi:\n10.1097/01.tp.0000229384.22217.15;00007890-200608270-00005 [pii]. PMID:16926589\n35. Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, et al. Mice fed rapamycin have an increase in\nlifespan associated with major changes in the liver transcriptome. PLoS One. 2014; 9(1):e83988. Epub\n2014/01/11.", "mimetype": "text/plain", "start_char_idx": 2127, "end_char_idx": 4866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "005d32e3-5583-4585-86d2-7ca38a37a851": {"__data__": {"id_": "005d32e3-5583-4585-86d2-7ca38a37a851", "embedding": null, "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4883ada8-3e80-4878-960d-f711f276cea5", "node_type": "4", "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "1ea26f987c168c3db7bfd1d1da7cbf138b4047d74eca53a8a90867291b8fe3c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b011f2c-8d09-41fb-993e-f3f3c0d71e17", "node_type": "1", "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "51ce866325366e772483c1be946b93e213e53a54c00abb7cac5bf730aa215729", "class_name": "RelatedNodeInfo"}}, "text": "Larsen JL, Bennett RG, Burkman T, Ramirez AL, Yamamoto S, Gulizia J, et al. Tacrolimus and siroli-\nmus cause insulin resistance in normal sprague dawley rats. Transplantation. 2006; 82(4):466\u201370. doi:\n10.1097/01.tp.0000229384.22217.15;00007890-200608270-00005 [pii]. PMID:16926589\n35. Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, et al. Mice fed rapamycin have an increase in\nlifespan associated with major changes in the liver transcriptome. PLoS One. 2014; 9(1):e83988. Epub\n2014/01/11. doi:10.1371/journal.pone.0083988 PMID: 24409289; PubMed Central PMCID:\nPMCPmc3883653.\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 17 / 18", "mimetype": "text/plain", "start_char_idx": 4370, "end_char_idx": 5065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0874d86f-4b03-4b83-ad4d-a0dbdb94acde": {"__data__": {"id_": "0874d86f-4b03-4b83-ad4d-a0dbdb94acde", "embedding": null, "metadata": {"page_label": "18", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1768b669-12b2-4cd6-b9d2-6ae05824fafe", "node_type": "4", "metadata": {"page_label": "18", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}, "hash": "c6ec30097c47cf11288ac255381341a26bfbdceaf175c5654f085db8a4a923e9", "class_name": "RelatedNodeInfo"}}, "text": "36. Ikeno Y, Hubbard GB, Lee S, Richardson A, Strong R, Diaz V, et al. Housing density does not influence\nthe longevity effect of calorie restriction. JGerontolA BiolSciMedSci. 2005; 60(12):1510\u20137. PMID:\n16424282\n37. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evi-\ndence for a phenotype. The journals of gerontology Series A, Biological sciences and medical sci-\nences. 2001; 56(3):M146\u201356. Epub 2001/03/17. PMID:11253156.\n38. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of oxi-\ndative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010; 143\n(5):802\u201312. Epub 2010/11/26. doi:10.1016/j.cell.2010.10.002 PMID: 21094524; PubMed Central\nPMCID: PMCPmc3018849.\n39. Kaeberlein M, Kennedy BK. Ageing: A midlife longevity drug? Nature. 2009; 460(7253):331\u20132. Epub\n2009/07/17. doi:10.1038/460331a PMID: 19606132.\n40. Someya S, Xu J, Kondo K, Ding D, Salvi RJ, Yamasoba T, et al. Age-related hearing loss in C57BL/6J\nmice is mediated by Bak-dependent mitochondrial apoptosis. Proc Natl Acad Sci U S A. 2009; 106\n(46):19432\u20137. Epub 2009/11/11. doi:10.1073/pnas.0908786106 PMID: 19901338; PubMed Central\nPMCID: PMCPmc2780799.\n41. Pack AI, Galante RJ, Maislin G, Cater J, Metaxas D, Lu S, et al. Novel method for high-throughput phe-\nnotyping of sleep in mice. Physiol Genomics. 2007; 28(2):232\u20138. doi: 00139.2006 [pii];doi:10.1152/\nphysiolgenomics.00139.2006 PMID: 16985007\n42. Judge JO, Davis RB III, Ounpuu S. Step length reductions in advanced age: the role of ankle and hip ki-\nnetics. JGerontolA BiolSciMedSci. 1996; 51(6):M303\u2013M12. PMID:8914503\n43. McFadyen MP, Kusek G, Bolivar VJ, Flaherty L. Differences among eight inbred strains of mice in\nmotor ability and motor learning on a rotorod. Genes Brain Behav. 2003; 2(4):214\u20139. PMID:12953787\n44. Schellinck HMC DP, Brown RE. How many ways can mouse behavioral experiments go wrong? Con-\nfounding variables in mouse models of neurodegenerative diseases and how to control them. In: Brock-\nman HJ, editor. Advances in the Study of Behavior. Burlington, VT: Academic Press; 2010. p. 255\u2013\n366.\n45. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, et al. Rapamycin-mediated lifespan\nincrease in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging\nCell. 2014; 13(3):468\u201377. Epub 2013/12/18. doi:10.1111/acel.12194 PMID: 24341993; PubMed Cen-\ntral PMCID: PMCPmc4032600.\n46. Aigouy B, Mirouse V. ScientiFig: a tool to build publication-ready scientific figures. Nature methods.\n2013; 10(11):1048. doi:10.1038/nmeth.2692 PMID: 24173380.\nHealth Effects of Long-term Rapamycin Treatment\nPLOS ONE | DOI:10.1371/journal.pone.0126644 May 15, 2015 18 / 18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/ref_doc_info": {"7d512a61-de38-447a-a6c1-9f55ead26529": {"node_ids": ["fd273028-a761-479a-955b-db9a96ef0aed"], "metadata": {"page_label": "1", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "f2c389ef-7ac9-4889-a00e-e9422247cf43": {"node_ids": ["66c3d439-7533-4971-9eaf-9ef123ea21fa", "e440c936-8845-41ef-ae37-81ee5b5bfeda"], "metadata": {"page_label": "2", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "9b36fe5b-efea-4cca-bf56-3159d8a45485": {"node_ids": ["5214b239-5dd4-4c82-81af-571cecb32e0d"], "metadata": {"page_label": "3", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "7adff462-401d-4722-a64b-c281aac4c2c1": {"node_ids": ["7d003f25-cc6b-4003-8a6c-48655b2ab041"], "metadata": {"page_label": "4", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "c7e54831-4721-4b3b-becb-0995300c1e35": {"node_ids": ["a0ebe0e9-c3c1-4dd4-a36c-113c9f7532e0"], "metadata": {"page_label": "5", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "bce6c492-eab6-4fe5-a7c0-263a4c76df20": {"node_ids": ["478a69a4-5c64-496b-b17d-9640c16962a0"], "metadata": {"page_label": "6", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "63c99209-dd7d-4863-bfb9-d159fbe4da6c": {"node_ids": ["956284ef-c6f5-4bcf-846b-dda4cd866cb5"], "metadata": {"page_label": "7", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "d53c4a56-25ca-4765-8555-2c6e73f1be68": {"node_ids": ["41336ba1-4aec-482d-899c-55fec953b60f", "d2fd057b-6c93-4bfc-ad5f-68e11eddeba5"], "metadata": {"page_label": "8", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "cc99e29d-03d8-4cdf-9d55-2978558f6e74": {"node_ids": ["39723756-c275-4326-b9ab-e6506069209e"], "metadata": {"page_label": "9", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "c75c254d-cbe8-4556-9976-a83caa83d43f": {"node_ids": ["9a2d691b-a8ae-4891-b3d7-f9b9b49ae8c9"], "metadata": {"page_label": "10", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "043f045f-3980-45ea-b870-2b2b83c018f4": {"node_ids": ["4cd0d83a-094b-4b50-92eb-580cd03b4585"], "metadata": {"page_label": "11", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "7c90146e-501d-474d-9c7f-ab57b5351320": {"node_ids": ["b40e3edc-bf1f-4bcf-be52-7fa01a44a1aa"], "metadata": {"page_label": "12", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "34644c3f-64c6-4384-9204-059621682d40": {"node_ids": ["cd9e472e-6a71-49d4-a183-96702490dcb1", "99b5201a-d4cf-4958-8043-462c16b34097"], "metadata": {"page_label": "13", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "f4bd806b-ad5e-4419-adc6-54afc3be9944": {"node_ids": ["887857b5-bae5-44a5-9087-6a2a6db068cb"], "metadata": {"page_label": "14", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "42955d0f-bba4-4584-a384-663bd0842e1c": {"node_ids": ["bae3a263-131c-4c30-a959-d2c6be021046"], "metadata": {"page_label": "15", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "3a90324c-72d1-4b69-94a0-80ddaf24396c": {"node_ids": ["252914df-5a2c-47ad-9c29-ba7e7b11f2c7", "0a6a0552-3563-4734-923e-6f7e02e6b9cb"], "metadata": {"page_label": "16", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "4883ada8-3e80-4878-960d-f711f276cea5": {"node_ids": ["2398bac3-473e-4e4b-bbd8-9fc37c331e49", "4b011f2c-8d09-41fb-993e-f3f3c0d71e17", "005d32e3-5583-4585-86d2-7ca38a37a851"], "metadata": {"page_label": "17", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}, "1768b669-12b2-4cd6-b9d2-6ae05824fafe": {"node_ids": ["0874d86f-4b03-4b83-ad4d-a0dbdb94acde"], "metadata": {"page_label": "18", "file_name": "rapa_fischer_2015.pdf", "file_path": "10k/rapa_fischer_2015.pdf", "file_type": "application/pdf", "file_size": 2740073, "creation_date": "2024-11-17", "last_modified_date": "2024-11-17"}}}}